{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:53:00Z","timestamp":1787028780618,"version":"build-2736575974"},"reference-count":72,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Kidney injury due to medications is a well-known clinical entity. Although drug-induced tubulointerstitial disease is commonly encountered, there are few reports in the literature associated with glomerular injury due to medications. The recognition of this type of kidney injury is crucial, as rapid discontinuation of the offending agent is critical to maximizing the likelihood of quick and effective renal function recovery. In this article, we present four cases that presented with nephrotic syndrome and were diagnosed with biopsy-proven podocytopathies, associated with exposure to a certain medication. All of them experienced complete resolution of nephrotic syndrome within days or weeks after discontinuation of the offending drug. We also present the data, which were found in a Medline search from the year 1963 until the present, regarding cases with podocytopathies associated with penicillamine, tamoxifen and the combination of pembrolizumab-axitinib, including only adult cases from the English literature. The Medline search revealed nineteen cases of penicillamine-induced minimal-change disease (MCD), one case of tamoxifen-induced MCD, and none associated with pembrolizumab-axitinib therapy. We also searched for the largest studies and meta-analyses regarding drug-induced podocytopathies after a Medline search from 1967 to the present of the English literature.<\/jats:p>","DOI":"10.3390\/life13061264","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T16:10:53Z","timestamp":1685203853000},"page":"1264","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug-Induced Podocytopathies: Report of Four Cases and Review of the Literature"],"prefix":"10.3390","volume":"13","author":[{"given":"Diamanto","family":"Athanasopoulou","sequence":"first","affiliation":[{"name":"Department of Nephrology and Transplantation, National and Kapodistrian University of Athens, Laiko Hospital, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1643-8923","authenticated-orcid":false,"given":"Sophia","family":"Lionaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, National and Kapodistrian University of Athens, Attiko Hospital, 124 62 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysanthi","family":"Skalioti","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Transplantation, National and Kapodistrian University of Athens, Laiko Hospital, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Liapis","sequence":"additional","affiliation":[{"name":"Department of Pathology, National and Kapodistrian University of Athens, Laiko Hospital, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5485-5328","authenticated-orcid":false,"given":"Panayiotis","family":"Vlachoyiannopoulos","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, National and Kapodistrian University of Athens, Laiko Hospital, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Boletis","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Transplantation, National and Kapodistrian University of Athens, Laiko Hospital, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ndt\/15.2.212","article-title":"Treatment-related acute renal failure in the elderly: A hospital-based prospective study","volume":"15","author":"Kohli","year":"2000","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_2","first-page":"27","article-title":"Keep in Mind the Spectrum of Drug-Induced Glomerular Diseases","volume":"13","author":"Izzedine","year":"2021","journal-title":"Kidney News"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/0192623318789399","article-title":"Drug-induced Glomerulonephritis: The Spectre of Biotherapeutic and Antisense Oligonucleotide Immune Activation in the Kidney","volume":"46","author":"Frazier","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"ref_4","unstructured":"(2022, October 11). The American Society of Health-System Pharmacists. Available online: https:\/\/www.drugs.com\/monograph\/penicillamine."},{"key":"ref_5","unstructured":"Stuart, M.C., Kouimtzi, M., and Hill, S.R. (2009). WHO Model Formulary 2008, WHO."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"652","DOI":"10.7326\/0003-4819-97-5-652","article-title":"D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): A retrospective analysis","volume":"97","author":"Steen","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","article-title":"High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial","volume":"42","author":"Clements","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.48.7.609","article-title":"Fatal aplastic anemia and liver toxicity caused by D-penicillamine treatment of rheumatoid arthritis","volume":"48","author":"Fishel","year":"1989","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","first-page":"67","article-title":"Penicillamine in the treatment of rheumatoid arthritis","volume":"70","author":"Camp","year":"1977","journal-title":"Proc. R. Soc. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7326\/0003-4819-97-5-659","article-title":"Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis","volume":"97","author":"Chalmers","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/bmj.296.6629.1083","article-title":"Natural course of penicillamine nephropathy: A long term study of 33 patients","volume":"296","author":"Hall","year":"1988","journal-title":"Br. Med. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/0971-4065.132024","article-title":"D-penicillamine-induced membranous nephropathy","volume":"24","author":"Tirumavalavan","year":"2014","journal-title":"Indian J. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejim.2006.03.001","article-title":"Penicillamine and nephrotic syndrome","volume":"17","author":"Habib","year":"2006","journal-title":"Eur. J. Intern. Med."},{"key":"ref_14","first-page":"183","article-title":"Minimal changes nephrotic syndrome associated to penicillamine treatment","volume":"24","author":"Basterrechea","year":"2004","journal-title":"Nefrologia"},{"key":"ref_15","first-page":"2","article-title":"Nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson\u2019s disease","volume":"22","author":"Kostadinova","year":"2014","journal-title":"Rev. Rom\u00e2n\u0103 Med. Lab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00000441-200012000-00008","article-title":"Rapidly progressive glomerulonephritis with d-penicillamine","volume":"320","author":"Nanke","year":"2000","journal-title":"Am. J. Med."},{"key":"ref_17","first-page":"67","article-title":"Extracapillary glomerulonephritis with anti-myeloperoxidase antibodies in 2 patients with systemic scleroderma treated with penicillamine D","volume":"28","author":"Kyndt","year":"1999","journal-title":"Presse Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2177\/jsci.22.354","article-title":"MPO-ANCA positive rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis during treatment with d-penicillamine","volume":"22","author":"Nanke","year":"1999","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF02207960","article-title":"Management of proteinuria secondary to penicillamine therapy in rheumatoid arthritis","volume":"11","author":"DeSilva","year":"1992","journal-title":"Clin. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2007.05.026","article-title":"D-Penicillamine\u2013Induced ANCA-Associated Crescentic Glomerulonephritis in Wilson Disease","volume":"50","author":"Clerbaux","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1111\/j.1572-0241.1998.00715.x","article-title":"Early onset of nephrotic syndrome after treatment with d-penicillamine in a patient with Wilson\u2019s disease","volume":"93","author":"Siafakas","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/03009747909108243","article-title":"Penicillamine induced membranous glomerulonephritis","volume":"28","author":"Neild","year":"1979","journal-title":"Scand. J. Rheumatol."},{"key":"ref_23","first-page":"661","article-title":"Penicillamine nephropathy in rheumatoid arthritis","volume":"80","author":"Bacon","year":"1976","journal-title":"Q. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1476-5381.1993.tb13840.x","article-title":"Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer","volume":"110","author":"Jordan","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"ref_25","unstructured":"(2022, August 10). Breast Cancer in Men. Cancer Help UK. Available online: https:\/\/www.cancerresearchuk.org\/about-cancer?page=5075."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1210\/me.2003-0202","article-title":"Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1","volume":"18","author":"Wang","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/humrep\/deh840","article-title":"Comparison of tamoxifen and clomiphene citrate for ovulation induction: A meta-analysis","volume":"20","author":"Steiner","year":"2005","journal-title":"Hum. Reprod."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1515\/jpem-2013-0052","article-title":"Tamoxifen therapy for the management of pubertal gynecomastia: A systematic review","volume":"26","author":"Lapid","year":"2013","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_29","first-page":"136","article-title":"Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty","volume":"15","author":"Neyman","year":"2017","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_30","unstructured":"(2022, August 07). Tamoxifen for Breast Cancer & Side Effects. Health and Life. Available online: https:\/\/healthlifeandstuff.com\/2009\/12\/tamoxifen-for-breast-cancer-side-effects\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/ki.2009.69","article-title":"17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes","volume":"75","author":"Catanuto","year":"2009","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Verma, R., Venkatareddy, M., Kalinowski, A., Li, T., Kukla, J., Mollin, A., Cara-Fuentes, G., Patel, S.R., and Garg, P. (2018). Nephrin is necessary for podocyte recovery following injury in an adult mature glomerulus. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198013"},{"key":"ref_33","first-page":"2373","article-title":"Oestrogen inhibits PTPRO to prevent the apoptosis of renal podocytes","volume":"17","author":"Ren","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_34","first-page":"2171","article-title":"Nephrotic syndrome and adjuvant treatment with tamoxifen for early breast cancer. Case report and review of the literature","volume":"14","author":"Lauro","year":"1994","journal-title":"Anticancer. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.juro.2013.04.130","article-title":"Risk factors for renal cell carcinoma in the VITAL study","volume":"190","author":"Macleod","year":"2013","journal-title":"J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/nep.13209","article-title":"Association between urologic malignancies and end-stage renal disease: A meta-analysis","volume":"24","author":"Kompotiatis","year":"2019","journal-title":"Nephrology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00280-021-04260-y","article-title":"Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function","volume":"87","author":"Mielczarek","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Semeniuk-Wojta\u015b, A., Lubas, A., Stec, R., Szczylik, C., and Niemczyk, S. (2016). Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122073"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.urolonc.2015.07.020","article-title":"Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma","volume":"33","author":"Pham","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s10147-014-0770-7","article-title":"Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib","volume":"20","author":"Miyake","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer\u2014Preclinical Background: CTLA-4 and PD-1 Blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin. Oncol."},{"key":"ref_45","first-page":"1664","article-title":"The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?","volume":"11","author":"Franzin","year":"2020","journal-title":"Frontiers"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ced.13867","article-title":"Vitiligo-like depigmentation iVitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers","volume":"44","author":"Liu","year":"2019","journal-title":"Clin. Exp. Derm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"AA Systematic Review of Immune Checkpoint Inhibitor\u2013Associated Glomerular Disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ekir.2020.02.028","article-title":"SAT-024 Glomerulonephritis induced by combination immunotherapy and VEGF inhibition with tyrosine kinase inhibitors (TKI)","volume":"5","author":"Lo","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/JOP.19.00647","article-title":"Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach","volume":"16","author":"Wood","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1681\/ASN.V1181439","article-title":"Lithium Nephrotoxicity: A Progressive Combined Glomerular and Tubulointerstitial Nephropathy","volume":"11","author":"Markowitz","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.03751106","article-title":"High sirolimus levels may induce focal segmental glomerulosclerosis de novo","volume":"2","author":"Letavernier","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2215\/CJN.07311009","article-title":"Treatment with IFN-alpha, -beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis","volume":"5","author":"Markowitz","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1681\/ASN.2009040450","article-title":"Development of focal segmental glomerulosclerosis after anabolic steroid abuse","volume":"21","author":"Herlitz","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2215\/CJN.14331218","article-title":"Risk of nephrotic syndrome for non-steroidal anti-inflammatory drug users: A case-control study","volume":"14","author":"Bakhriansyah","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/ndt\/15.7.1056","article-title":"Minimal change nephrotic syndrome associated with rifampicin treatment","volume":"15","author":"Keisuke","year":"2000","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000166685","article-title":"Rifampin-induced nephrotic syndrome and acute interstitial nephritis","volume":"3","author":"Neugarten","year":"1983","journal-title":"Am. J. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3349\/ymj.2015.56.2.582","article-title":"Rifampicin-induced minimal Change disease is improved after cessation of rifampicin without steroid therapy","volume":"56","author":"Dong","year":"2015","journal-title":"Yonsei Med. J."},{"key":"ref_60","first-page":"22","article-title":"Minimal change disease related to rifampicin presenting with acute renal failure during treatment for latent tuberculosis infection: A case report","volume":"97","author":"Kim","year":"2018","journal-title":"Medicine"},{"key":"ref_61","first-page":"5546942","article-title":"Rifampicin-Associated Secondary Minimal Change Disease Presenting with Nephrotic Syndrome in a Pulmonary Tuberculosis Patient","volume":"2021","author":"Sathi","year":"2021","journal-title":"Case Rep. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jama.1996.03540060042033","article-title":"Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs","volume":"276","author":"Radford","year":"1996","journal-title":"JAMA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2125.1999.00869.x","article-title":"Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism","volume":"47","author":"Ravnskov","year":"1999","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.2215\/CJN.08090719","article-title":"NSAIDs and Nephrotic Syndrome","volume":"14","author":"Praga","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/ki.2010.89","article-title":"Acute interstitial nephritis","volume":"77","author":"Praga","year":"2010","journal-title":"Kidney Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.ajkd.2013.03.045","article-title":"Membranous nephropathy and nonsteroidal anti-inflammatory agents","volume":"62","author":"Nawaz","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","article-title":"Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: Implications for renal safety","volume":"22","author":"Haiker","year":"2008","journal-title":"Toxicol. In Vitro"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000046326","article-title":"Rapidly progressive glomerulonephritis due to rifampicin therapy","volume":"90","author":"Yoshioka","year":"2002","journal-title":"Nephron"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/0002-9343(88)90077-0","article-title":"Focal segmental glomerulosclerosis in patients receiving lithium carbonate","volume":"84","author":"Santella","year":"1988","journal-title":"Am. J. Med."},{"key":"ref_70","first-page":"109","article-title":"Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature","volume":"8","author":"Gianassi","year":"2019","journal-title":"World J. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/ckj\/sfab114","article-title":"Renal diseases secondary to interferon-\u03b2 treatment: A multicentre clinico-pathological study and systematic literature review","volume":"14","author":"Dauvergne","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_72","first-page":"59A","article-title":"Cardiotrophin like cytokine-1: Candidate for the focal glomerular sclerosis permeability factor","volume":"19","author":"Savin","year":"2008","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/6\/1264\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:43:13Z","timestamp":1760125393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/6\/1264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":72,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["life13061264"],"URL":"https:\/\/doi.org\/10.3390\/life13061264","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]}}}